|
|
Article: Studies from University of Halle-Wittenberg yield new data on adenocarcinoma.
- Article from:
- Gene Therapy Weekly
- Article date:
- November 12, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
"Transforming growth factor-beta 1 (TGF-beta 1) is over-expressed in a variety of malignant epithelial tumors and was suggested to be a marker of colorectal cancer. Moreover, there is growing evidence that TGF-beta 1 contributes to tumor progression by regulating tumor cell proliferation and differentiation, inducing a favorable tumor microenvironment, promoting migration and invasion, and suppressing macrophage cytotoxicity," scientists in Halle, Germany report (see also Adenocarcinoma).
"Therefore, we stably transfected an anti-TGF-beta 1 hammerhead ribozyme into the human colorectal adenocarcinoma cell line HRT-18. Expression of this ribozyme resulted in ...